- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
NeuBase Therapeutics is a biotechnology business based in the US. NeuBase Therapeutics shares (NBSE) are listed on the NASDAQ and all prices are listed in US Dollars. NeuBase Therapeutics employs 37 staff and has a market cap (total outstanding shares value) of 0.00.
What's in this guide?
Our top picks for where to buy NeuBase Therapeutics stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy NeuBase Therapeutics stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – NBSE. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy NeuBase Therapeutics stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
NeuBase Therapeutics stock price (NASDAQ: NBSE)
Use our graph to track the performance of NBSE stocks over time.NeuBase Therapeutics shares at a glance
Information last updated 2024-11-17.
| 52-week range | $0.36 - $1.15 |
|---|---|
| 50-day moving average | $0.47 |
| 200-day moving average | $0.72 |
| Wall St. target price | $140.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-18.60 |
Is it a good time to buy NeuBase Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
NeuBase Therapeutics financials
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -43.03% |
| Return on equity TTM | -93.46% |
| Profit margin | 0% |
| Book value | $2.45 |
| Market Capitalization | $1.4 million |
TTM: trailing 12 months
NeuBase Therapeutics share dividends
We're not expecting NeuBase Therapeutics to pay a dividend over the next 12 months.
Have NeuBase Therapeutics's shares ever split?
NeuBase Therapeutics's shares were split on a 1:20 basis on 14 June 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeuBase Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NeuBase Therapeutics shares which in turn could have impacted NeuBase Therapeutics's share price.
NeuBase Therapeutics share price volatility
Over the last 12 months, NeuBase Therapeutics's shares have ranged in value from as little as $0.36 up to $1.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeuBase Therapeutics's is 0.945. This would suggest that NeuBase Therapeutics's shares are less volatile than average (for this exchange).
NeuBase Therapeutics overview
NeuBase Therapeutics, Inc. , a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania. .
Frequently asked questions
What percentage of NeuBase Therapeutics is owned by insiders or institutions?Currently 13.378% of NeuBase Therapeutics shares are held by insiders and 11.872% by institutions. How many people work for NeuBase Therapeutics?
Latest data suggests 37 work at NeuBase Therapeutics. When does the fiscal year end for NeuBase Therapeutics?
NeuBase Therapeutics's fiscal year ends in September. Where is NeuBase Therapeutics based?
NeuBase Therapeutics's address is: 350 Technology Drive, Pittsburgh, PA, United States, 15219 What is NeuBase Therapeutics's ISIN number?
NeuBase Therapeutics's international securities identification number is: US64132K1025 What is NeuBase Therapeutics's CUSIP number?
NeuBase Therapeutics's Committee on Uniform Securities Identification Procedures number is: 67778H101
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Trading for Beginners: 9 Best Trading Platforms to Get Started
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
-
10 Best Stock Apps of 2024 to Elevate Your Mobile Trading
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
10 Best Brokerage Accounts for Trading and Investing in 2024
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question